| COVID-19 vaccines vs variants — Determining how much immunity is enough | FDA takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine |
|---|---|
| FDA for emergency use authorization | Centers for Disease Control and Prevention |
Interim considerations for COVID-19 vaccination of healthcare personnel and long-term care facility residents.
| Use of Pfizer-BioNTech COVID-19 vaccine: Clinical considerations | Centers for Disease Control and Prevention |
|---|---|
| Centers for Disease Control and Prevention | Understanding viral vector COVID-19 vaccines |
| Centers for Disease Control and Prevention | Centers for Disease Control and Prevention |
|---|---|
| Vaccination considerations for persons with underlying medication conditions | Moderna announces primary efficacy analysis in phase 3 COVE study for its COVID-19 vaccine candidate and filing today with the U |
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.
10